These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 31010842)
21. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Polański R; Hodgkinson CL; Fusi A; Nonaka D; Priest L; Kelly P; Trapani F; Bishop PW; White A; Critchlow SE; Smith PD; Blackhall F; Dive C; Morrow CJ Clin Cancer Res; 2014 Feb; 20(4):926-937. PubMed ID: 24277449 [TBL] [Abstract][Full Text] [Related]
22. Sex and Cross-Sex Testosterone Treatment Alters Gamma-Hydroxybutyrate Acid Toxicokinetics and Toxicodynamics in Rats. Zhang Q; Wei H; Lee A; Felmlee MA Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38276513 [TBL] [Abstract][Full Text] [Related]
23. Identification of key binding site residues of MCT1 for AR-C155858 reveals the molecular basis of its isoform selectivity. Nancolas B; Sessions RB; Halestrap AP Biochem J; 2015 Feb; 466(1):177-88. PubMed ID: 25437897 [TBL] [Abstract][Full Text] [Related]
24. GHB toxicokinetics and renal monocarboxylate transporter expression are influenced by the estrus cycle in rats. Wei H; Cao J; Fallert T; Yeo S; Felmlee MA BMC Pharmacol Toxicol; 2023 Nov; 24(1):58. PubMed ID: 37919807 [TBL] [Abstract][Full Text] [Related]
25. Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. Morris ME; Felmlee MA AAPS J; 2008 Jun; 10(2):311-21. PubMed ID: 18523892 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma. Noble RA; Bell N; Blair H; Sikka A; Thomas H; Phillips N; Nakjang S; Miwa S; Crossland R; Rand V; Televantou D; Long A; Keun HC; Bacon CM; Bomken S; Critchlow SE; Wedge SR Haematologica; 2017 Jul; 102(7):1247-1257. PubMed ID: 28385782 [TBL] [Abstract][Full Text] [Related]
27. In Vitro and In Vivo Evidence for Active Brain Uptake of the GHB Analog HOCPCA by the Monocarboxylate Transporter Subtype 1. Thiesen L; Kehler J; Clausen RP; Frølund B; Bundgaard C; Wellendorph P J Pharmacol Exp Ther; 2015 Aug; 354(2):166-74. PubMed ID: 25986445 [TBL] [Abstract][Full Text] [Related]
28. Self-administration of gamma-hydroxybutyric acid (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons. Goodwin AK; Kaminski BJ; Weerts EM Psychopharmacology (Berl); 2013 Feb; 225(3):637-46. PubMed ID: 22945514 [TBL] [Abstract][Full Text] [Related]
29. Intoxications due to ingestion of gamma-butyrolactone: organ distribution of gamma-hydroxybutyric acid and gamma-butyrolactone. Lenz D; Rothschild MA; Kröner L Ther Drug Monit; 2008 Dec; 30(6):755-61. PubMed ID: 18824955 [TBL] [Abstract][Full Text] [Related]
30. The gamma-hydroxybutyrate model of absence seizures: correlation of regional brain levels of gamma-hydroxybutyric acid and gamma-butyrolactone with spike wave discharges. Snead OC Neuropharmacology; 1991 Feb; 30(2):161-7. PubMed ID: 2030821 [TBL] [Abstract][Full Text] [Related]
33. In Vitro and In Vivo Efficacy of AZD3965 and Alpha-Cyano-4-Hydroxycinnamic Acid in the Murine 4T1 Breast Tumor Model. Guan X; Morris ME AAPS J; 2020 Jun; 22(4):84. PubMed ID: 32529599 [TBL] [Abstract][Full Text] [Related]
34. In Vivo Anticancer Activity of AZD3965: A Systematic Review. Silva A; Antunes B; Batista A; Pinto-Ribeiro F; Baltazar F; Afonso J Molecules; 2021 Dec; 27(1):. PubMed ID: 35011413 [TBL] [Abstract][Full Text] [Related]
35. Risk assessment of GBL as a substitute for the illicit drug GHB in the Netherlands. A comparison of the risks of GBL versus GHB. van Amsterdam J; Brunt T; Pennings E; van den Brink W Regul Toxicol Pharmacol; 2014 Nov; 70(2):507-13. PubMed ID: 25204614 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Bola BM; Chadwick AL; Michopoulos F; Blount KG; Telfer BA; Williams KJ; Smith PD; Critchlow SE; Stratford IJ Mol Cancer Ther; 2014 Dec; 13(12):2805-16. PubMed ID: 25281618 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer. Emi Y; Sumiyoshi Y; Oki E; Kakeji Y; Fukui Y; Maehara Y Fukuoka Igaku Zasshi; 2007 Dec; 98(12):418-24. PubMed ID: 18260367 [TBL] [Abstract][Full Text] [Related]
38. The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol. Schep LJ; Knudsen K; Slaughter RJ; Vale JA; Mégarbane B Clin Toxicol (Phila); 2012 Jul; 50(6):458-70. PubMed ID: 22746383 [TBL] [Abstract][Full Text] [Related]
39. Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition. Lamb R; Harrison H; Hulit J; Smith DL; Lisanti MP; Sotgia F Oncotarget; 2014 Nov; 5(22):11029-37. PubMed ID: 25415228 [TBL] [Abstract][Full Text] [Related]
40. Gamma-butyrolactone (GBL) disruption of passive avoidance learning in the day-old chick appears to be due to its effect on GABAB not gamma-hydroxybutyric [corrected] acid (GHB) receptors. Sherry JM; Hazi A; Hale MW; Milsome SL; Crowe SF Behav Brain Res; 2009 Feb; 197(2):347-55. PubMed ID: 18948143 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]